Mozavaptan
As of the edition of 20 October 2026, Mozavaptan is a small molecule: marketed, first approved in 2006 (JP); acts on AVPR2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2006
- Kind
- Small molecule
- First approved
- 26 July 2006 (JP)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Otsuka
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| AVPR2 | Vasopressin V2 receptor | P30518 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Otsuka | Originator | 2006 to now |